NCT03280264

Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism

An Intra-Subject Dose-Adjustment Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism Who Are Unable to Undergo Parathyroidectomy or Relapse After Parathyroidectomy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Kyowa Kirin Co., Ltd. · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy of KHK7580 orally administered up to 24 weeks for hypercalcemia in patient with parathyroid carcinoma or primary hyperparathyroidism who are unable to undergo parathyroidectomy or relapse after parathyroidectomy.

Conditions

• Parathyroid Carcinoma
• Primary Hyperparathyroidism

Interventions

Type	Name	Description
DRUG	KHK7580	oral administration

Timeline

• Start date: 2017-08-30
• Primary completion: 2019-04-09
• Completion: 2019-04-09
• First posted: 2017-09-12
• Last updated: 2021-05-27
• Results posted: 2021-05-27

Locations

1 site across 1 country: Japan